	Application No.	Applicant(s)
Notice of Allowability	10/820,067	FLECHTNER ET AL.
	Examiner	Art Unit
	Danisasia D. Dismaal	1619
<u> </u>	Benjamin P. Blumel	1648
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>April 6, 2007</u> .		
2. The allowed claim(s) is/are <u>1-20, 22-24 and 28-51</u> .		
 3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of		
Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
	,	
	•	
	1	
Attachment(s)	:	al Datant Application
1. Notice of References Cited (PTO-892)	5. Notice of Informa	
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summ Paper No./Mail	
3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	Paper No./Mail 7. ⊠ Examiner's Ame	ndment/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. Examiner's State	ement of Reasons for Allowance
<u>-</u> .	9. Other	
		•

DETAILED ACTION

This Office Action is in response to Applicants arguments/remarks dated April 6, 2007.

Applicant's arguments have been considered on the grounds they are objecting to. All rejections are withdrawn in view of Applicant's amendments to the claims and in view of Examiner's Amendments (stated below). The claims are in condition for allowance.

Response to Declaration under 37 CFR 1.132

The declaration under 37 CFR 1.132 filed March 21, 2007 is sufficient to overcome the rejection of claims 1-4, 11-14, 28, 29, 32, 35, 36 and 39-43 based upon 35 USC § 103(a).

Election/Restrictions

Claims 1-4, 11-14, 28, 29, 32, 35, 36, 39-43 and 47-51 are directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(b), claims 5-10, 15-20, 22-24 and 44-46 are directed to the process of making or using the allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104. Claims 25-27, directed to the invention(s) of a method of treating cancer require all the limitations of an allowable product claim, and have NOT been rejoined.

Because a claimed invention previously withdrawn from consideration under 37 CFR 1.142 has been rejoined, the restriction requirement between groups I-III and V as set forth in the Office action mailed on May 16, 2006 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any

Application/Control Number: 10/820,067

Art Unit: 1648

claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Adriane M. Antler on July 2, 2007.

In the claims:

Claims 25-27 are cancelled.

The following is an examiner's statement of reasons for allowance: claims 1-20, 22-24 and 28-51 are free of the art and are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Application/Control Number: 10/820,067

Art Unit: 1648

Summary

Page 4

Claims 1-20, 22-24 and 28-51 are allowed.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Benjamin P. Blumel whose telephone number is 571-272-4960. The examiner can normally be reached on M-F, 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-1600. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Benjamin P Blumel/

Examiner

Art Unit 1648

SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600